VIVS — VivoSim Labs Share Price
0.000.00%
Last trade - 00:00- $3.17m
- $2.26m
- $0.11m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 8.7 | ||
| Price to Tang. Book | 8.7 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 25.95 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -1384.56% | ||
| Return on Equity | -378.4% | ||
| Operating Margin | -10293.44% | ||
Financial Summary
| Year End 31st Mar | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 2.2 | n/a | 1.5 | 0.37 | 0.11 | 0.17 | 0.2 | -48.78% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
VivoSim Labs, Inc., formerly Organovo Holdings, Inc., is a clinical-stage biotechnology company. The Company is developing drugs that are demonstrated to be effective in three-dimensional (3D) human tissues as candidates for drug development. It focuses on developing novel treatment approaches in inflammatory bowel disease (IBD). Its proprietary technology is used to build 3D human tissues that mimic key aspects of native human tissue composition, architecture, function, and disease. It uses its proprietary technology to build functional 3D human tissues that mimic key aspects of native human tissue composition, architecture, function, and disease. Its 3D human tissue platform is multifaceted. Its NovoGen Bioprinters can also dispense pure hydrogel formulations, provided the physical properties of the hydrogel are compatible with the dispensing parameters.
Directors
- Keith Murphy CHM (49)
- Thomas Hess PRE (57)
- Jeffrey Miner CSO (52)
- Thomas Jurgensen GCN (64)
- Douglas Cohen IND (50)
- David Gobel IND (68)
- Alison Milhous IND (42)
- Adam Stern IND (57)
- Last Annual
- March 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- January 27th, 2012
- Public Since
- August 2nd, 2013
- No. of Shareholders
- 82
- No. of Employees
- 12
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 1,701,795
- Address
- 11555 Sorrento Valley Road, Suite 100, SAN DIEGO, 92121
- Web
- https://organovo.com/
- Phone
- +1 8582241000
- Auditors
- ROSENBERG RICH BAKER BERMAN, P.A.
Upcoming Events for VIVS
Q1 2025 Organovo Holdings Inc Earnings Release
Similar to VIVS
Abeona Therapeutics
NASDAQ Capital Market
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
Aclarion
NASDAQ Capital Market
FAQ
What is the VivoSim Labs share price?
As of Today at 24:01 UTC, shares in VivoSim Labs are trading at . This share price information is delayed by 15 minutes.
How has the VivoSim Labs share price performed this year?
Shares in VivoSim Labs last closed at and the price had moved by -84.31% over the past 365 days. In terms of relative price strength the VivoSim Labs share price has underperformed the S&P500 Index by -85.52% over the past year.
What are the analyst and broker recommendations for VivoSim Labs?
The overall consensus recommendation for VivoSim Labs is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the VivoSim Labs dividend yield?
VivoSim Labs does not currently pay a dividend.
Does VivoSim Labs pay a dividend?
VivoSim Labs does not currently pay a dividend.
When does VivoSim Labs next pay dividends?
VivoSim Labs does not currently pay a dividend.
How do I buy VivoSim Labs shares?
To buy shares in VivoSim Labs you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of VivoSim Labs?
As of the previous close price of , shares in VivoSim Labs had a market capitalisation of $3.17m.
Where are VivoSim Labs shares listed?
Here are the trading details for VivoSim Labs:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: VIVS
What kind of share is VivoSim Labs?
Based on an overall assessment of its quality, value and momentum VivoSim Labs is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a VivoSim Labs share price forecast for 2025?
We could not find analyst target price data for this security.
Find out moreWhat is the trend in the VivoSim Labs share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like VivoSim Labs. Over the past six months, its share price has underperformed the S&P500 Index by -63.03%.
As of the last closing price of , shares in VivoSim Labs were trading -64.37% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the VivoSim Labs PE Ratio?
The VivoSim Labs PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at .
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of VivoSim Labs?
VivoSim Labs' management team is headed by:
- Keith Murphy - CHM
- Thomas Hess - PRE
- Jeffrey Miner - CSO
- Thomas Jurgensen - GCN
- Douglas Cohen - IND
- David Gobel - IND
- Alison Milhous - IND
- Adam Stern - IND